[1] SIEGEL R L,MILLER K D,JEMA A L.Cancer statistics,2020[J].CA Cancer J Clin,2020,70(1):7-30.
[2] 郑荣寿,孙可欣,张思维,等.2015年中国恶性肿瘤流行情况分析[J].中华肿瘤杂志,2019,41(1):19-28.
[3] WERNER H M J,SALVESEN H B.Current status of molecular biomarkers in endometrial cancer[J].Curr Oncol Rep,2014,16(9):403.
[4] 向阳,孙建衡.难治性妇科恶性肿瘤的处理策略[J].中华妇产科杂志,2018,43(10):721-723.
[5] ZHU X,LI S,XU B,et al.Cancer evolution:A means by which tumors evade treatment[J].Biomed Pharmacother,2021,133:111016
[6] LONG G V,DUMMER R,HAMID O,et al.Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma(ECHO-301/KEYNOTE-252):a phase 3,randomised,doubleblind study[J].Lancet Oncol,2019,20(8):1083-1097.
[7] RECK M,MOK T S K,NISHIO M,et al.Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer(IMpower150):key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised,open-label phase 3 trial[J].Lancet Respir Med,2019,7(5):387-401.
[8] ABU A A,RAVEENDRAN R,GIBSON D.A lipophilic pt(IV) oxaliplatin derivative enhances antitumor activity[J].J Med Chem,2016,59(19):9035.
[9] PETER M B,LIU Y P,PARK G Y,et al.A subset of platinum-containing chemotherapeutic agents kills cells by inducing ribosome biogenesis stress[J].Nat Med,2017,23(4):461-471.
[10] SUN H T,ZHOU H J,HU Y L,et al.Effect of oxaliplatin on the growth of tumor and angiopoietin-2 in micemodels of endometrial carcinoma[J].J Southeast Univ(MedSciEdi),2011,30(3):464-468.
[11] DE PALMA M,BIZIATO D,PETROVA T V.Microenvironmental regulation of tumour angiogenesis[J].Nat Rev Cancer,2017,17(8):457-474.
[12] HARRELL C R,SIMOVIC MARKOVIC B,FELLABAUM C,et al.Molecular mechanisms underlying therapeutic potential of pericytes[J].J Biomed Sci,2018,25:21.
[13] JELTSCH M,LEPPÄNEN V M,SAHARINEN P,et al.Receptor tyrosine kinase-mediated angiogenesis[J].Cold Spring Harb Perspect Biol,2013,5:a009183.
[14] 程子芸,赵建飞,丁艺,等.小分子靶向药物在子宫内膜癌中的临床研究进展[J].东南大学学报(医学版),2016,35(5):817-820.
[15] DE PALMA M,BIZIATO D,PETROVA T V.Microenvironmental regulation of tumour angiogenesis[J].Nat Rev Cancer,2017,17(8):457-474.
[16] SORMENDI S,WIELOCKX B.Hypoxia pathway proteins as central mediators of metabolism in the tumor cells and their microenvironmen[J].Front Immunol,2018,9:40.
[17] JAIN R K.Normalization of tumor vasculature:an emerging concept in antiangiogenic therapy[J].Science,2005,307:58-62.
[18] KUMAR V,YADAVILLI S,KANNAN R.A review on RNAi therapy for NSCLC:Opportunities and challenges[J].Wiley Interdiscip Rev Nanomed Nanobiotechnol,2021,13(2):e1677.
[19] MANI S,GRAHAM M A,BREGMAN D B,et al.Oxaliplatin:a review of evolving concepts[J].Cancer Investig,2002,20:246-263.
[20] DIFRANCESCO A M,RUGGERIERO A,RICCARDI R.Cellular and molecular aspects of drugs of the future:oxaliplatin[J].Cell Mol Life Sci,2002,59:1914-1927.
[21] 王萧.实验动物学实验指导[M].北京:北京科学技术出版社,2020:7.
[22] 孔祥怡,周怀君.miRNA-30c及其靶基因MTA-1在子宫内膜癌裸鼠皮下移植瘤中的作用[J].东南大学学报(医学版),2016,35(3):364-370.
[23] FRACASSO P M,BLESSING J A,MOLPUS K L,et al.Phase II study of oxaliplatin as second-line chemotherapy in endometrial carcinoma:A Gynecologic Oncology Group study[J].Gynecologic Oncology,2006,103:523-526.
[24] LIU B R,SUN Y C,QIAN X P,et al.An experimental study of low dose oxaliplatin inhibiting tumour angiogenesis in vivo[J].Journal of Clinical Medicine in Practice,2009,13(2):33-43.
[25] FAN F,GRAY M J,DALLAS N A,et al.Effect of chemotherapeutic stress on induction of vascular endothelial growth factor family members and receptors in human colorectal cancer cells[J].Mol Cancer Ther,2008,7(9):3064-3070.
[26] VIALLARD C,LARRIVÉE B.Tumor angiogenesis and vascular normalization:alternative therapeutic targets[J].Angiogenesis,2017,20:409-426.
[27] JAIN R K.Antiangiogenesis strategies revisited:from starving tumors to alleviating hypoxia[J].Cancer Cell,2014,26:605-622.
[28] 林建伟.RNA干扰技术在临床中的应用[J].世界科学,2011(1):61.
[29] CHEN T,DENG C S.Inhibitory effect of siRNA targeting survivin in gastric cancer MGC-803 cells[J].Int Immunopharmacol,2008,8:1006-1011.
[30] PUSHPARAJ P N,H'NG S C,MELENDEZ A J,et al.Refining siRNA in vivo transfection:Silencing SPHK1 reveals its key role in C5a-induced inflammation in vivo[J].Int J Biochem Cell B,2008,40:1817-1825.
[31] PEER D,PARK E J,MORISHITA Y,et al.Systemic leukocytedirected siRNA delivery revealing cyclin D1 as an anti-inflammatory target[J].Science,2008,319:627-630.
[32] URBAN-KLEIN B,WERTH S,ABUHARBEID S,et al.RNAi-mediated gene-targeting through systemic application of polyethylenimine(PEI)-complexed siRNA in vivo[J].Gene Ther,2005,12(5):461-466.
[33] PARK K,LEE M Y,KIM K S,et al.Target specific tumor treatment by VEGF siRNA complexed with reducible polyethyleneimine-hyaluronic acid conjugate[J].Biomaterials,2010,31:5258-5265.
[34] SHEN B J.Suppression of ocular neovascularization with siRNA targeting VEGF receptor 1[J].Gene Ther,2006,13:225-234. |